Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.

Capecchi, Pier Leopoldo; Lazzerini, Pietro Enea

Capecchi, Pier Leopoldo; Lazzerini, Pietro Enea.

Afiliação

Capecchi PL; Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
Lazzerini PE; Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

Ann Rheum Dis ; 81(11): e214, 2022 11.

Article em En | MEDLINE | ID: mdl-32737112

Assuntos

Tratamento Farmacológico da COVID-19; Anticorpos Monoclonais Humanizados/uso terapêutico; Humanos; Interleucina-6

Palavras-chave

antirheumatic agents; cytokines; therapeutics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google